Results 21 to 30 of about 161,275 (301)

Evaluation of the Interleukin-1 Receptor Antagonist and Immunoregulatory Interleukin-10 in the Middle Ear in Chronic Otitis Media With Effusion in Children With and Without Atopy [PDF]

Clinical and Experimental Otorhinolaryngology, 2016
Objectives The role of pro-inflammatory cytokines in the course of chronic otitis media with effusion (COME) has been documented. However, there are fewer studies on the action of anti-inflammatory cytokines in the middle ear. We sought determine whether
Beata Zielnik-Jurkiewicz, Wanda Stankiewicz-Szymczak   +1 more
doaj   +1 more source

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse

Mediators of Inflammation, 1992
In this work we have focused on the ability of interleukin-1 to induce an acute phase protein response and a degranulation of polymorphonuclear leukocytes in vivo.
P. Bjrök, K. Ohlsson
doaj   +1 more source

Rescued Chondrogenesis of Mesenchymal Stem Cells under Interleukin 1 Challenge by Foamyviral Interleukin 1 Receptor Antagonist Gene Transfer

Frontiers in Pharmacology, 2017
Background: Mesenchymal stem cells (MSCs) and their chondrogenic differentiation have been extensively investigated in vitro as MSCs provide an attractive source besides chondrocytes for cartilage repair therapies.
Nicole Armbruster, Nicole Armbruster, Jennifer Krieg, Jennifer Krieg, Manuel Weißenberger, Carsten Scheller, Andre F. Steinert   +6 more
doaj   +1 more source

Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist

Communications Biology, 2021
Tan, Lash et al. show that blocking the Interleukin-1 receptor promotes rapid wound closure in diabetic mice. They engineered a matrix binding form of Interleukin-1 receptor antagonist (IL-1Ra) that has the ability of precise localisation and retention ...
Jean L. Tan, Blake Lash, Rezvan Karami, Bhavana Nayer, Yen-Zhen Lu, Celeste Piotto, Ziad Julier, Mikaël M. Martino   +7 more
doaj   +1 more source

Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]

, 2012
Peer reviewedPublisher ...
Walsh, Garry M.
core   +2 more sources

IL1RN (interleukin 1 receptor antagonist) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2014
Review on IL1RN, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Gómez-Flores-Ramos, L, Torres-Flores, J, Gallegos-Arreola, MP   +2 more
openaire   +2 more sources

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

OncoImmunology, 2019
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor.
Razelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, Mark Saunders, Qian Wu, Michael Stecher, Prasant Mohanty, Charles A. Dinarello, John Simard   +8 more
doaj   +1 more source

Catecholamine stress alters neutrophil trafficking and impairs wound healing by β2-adrenergic receptor-mediated upregulation of IL-6. [PDF]

, 2014
Stress-induced hormones can alter the inflammatory response to tissue injury; however, the precise mechanism by which epinephrine influences inflammatory response and wound healing is not well defined.
Byrne, Barbara A, Gorouhi, Farzam, Granick, Jennifer L, Isseroff, Rivkah R, Kim, Min-Ho, Ramirez, Sandra, Simon, Scott I, Soulika, Athena M   +7 more
core   +2 more sources

Studying the Pharmacokinetics of Interleukin-1RA Mutants

Bioscientific Review, 2019
The two antagonists for interleukin-1 (IL-1) system are IL-1α, and IL-1β. IL-1 receptor antagonist (IL-1RA) is another naturally occurring non-competitive antagonist. All three antagonists are bound to two receptors that are IL-R1 and IL-1R2.
Iqra Khuzaima, Kanwal Iftikhar, Uroosa Tabarruk, Haleema Sadia, Khadija Shami   +4 more
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source